[DOI] [PMC free article] [PubMed] [Google Scholar] 45.Zhou C.C., Yang X., Hua X., Liu J., Fan M.B., Li G.Q., Song J., Xu T.Y., Li Z.Y., Guan Y.F., et al
Does this mean compounded semaglutide is dangerous
Anyone receiving retatrutide within a clinical trial should seek prompt medical advice from their trial team if they experience any of the following: Persistent or severe vomiting that prevents adequate fluid or food intake Signs of dehydration , including dizziness, reduced urination, or extreme thirst Severe or persistent abdominal pain , which may rarely indicate pancreatitis or a gallbladder problem Right upper quadrant pain, fever, or jaundice , which may suggest acute gallbladder disease (cholelithiasis or cholecystitis) a recognised risk with GLP-1-based therapies and with rapid weight loss [11] [12] Symptoms of hypoglycaemia (particularly if taking concomitant insulin or sulphonylureas), such as shakiness, sweating, or confusion Injection site reactions that are worsening, infected, or not resolving Retatrutide has not been studied in pregnancy or breastfeeding, and use during pregnancy or whilst breastfeeding is not recommended until safety data are available
These are signs that the glucagon component is driving energy expenditure at a level that meaningfully contributes to the overall weight loss beyond what GLP-1 and GIP provide alone
Stress and sleep optimization Chronic stress and poor sleep are both potent inflammatory stimuli that lower the flare threshold for autoimmune patients
This product is not intended for the treatment of Type 1 Diabetes
